A249420 Stock Overview
Develops, manufactures, and sells pharmaceutical products in South Korea.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Ildong Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩16,700.00 |
52 Week High | ₩24,450.00 |
52 Week Low | ₩11,980.00 |
Beta | 0.99 |
11 Month Change | 22.17% |
3 Month Change | 10.01% |
1 Year Change | 3.53% |
33 Year Change | 15.97% |
5 Year Change | 10.28% |
Change since IPO | -12.29% |
Recent News & Updates
Revenues Not Telling The Story For Ildong Pharmaceutical Co., Ltd. (KRX:249420) After Shares Rise 33%
Aug 20Is Ildong Pharmaceutical (KRX:249420) A Risky Investment?
Aug 12Shareholder Returns
A249420 | KR Pharmaceuticals | KR Market | |
---|---|---|---|
7D | 5.2% | 4.5% | 2.9% |
1Y | 3.5% | 13.5% | 4.4% |
Return vs Industry: A249420 underperformed the KR Pharmaceuticals industry which returned 13.5% over the past year.
Return vs Market: A249420 matched the KR Market which returned 4.4% over the past year.
Price Volatility
A249420 volatility | |
---|---|
A249420 Average Weekly Movement | 7.2% |
Pharmaceuticals Industry Average Movement | 6.4% |
Market Average Movement | 6.5% |
10% most volatile stocks in KR Market | 12.1% |
10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A249420's share price has been volatile over the past 3 months.
Volatility Over Time: A249420's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1941 | 1,007 | Yun Paul Woongsup | www.ildong.com |
Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-histamine drugs, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central nervous system, dental, endocrine and metabolic system, gastrointestinal system, respiratory system, topical preparation, and urogenital system applications. It also provides raw material drugs; health foods and foods; cosmetics; medical devices for scar treatment; and other drugs for treating thick wounds, osteoarthritis, periarthritis of shoulder, and artificial tears, as well as feminine cleanser products.
Ildong Pharmaceutical Co., Ltd. Fundamentals Summary
A249420 fundamental statistics | |
---|---|
Market cap | ₩466.47b |
Earnings (TTM) | -₩69.35b |
Revenue (TTM) | ₩605.80b |
0.8x
P/S Ratio-6.7x
P/E RatioIs A249420 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A249420 income statement (TTM) | |
---|---|
Revenue | ₩605.80b |
Cost of Revenue | ₩387.95b |
Gross Profit | ₩217.85b |
Other Expenses | ₩287.20b |
Earnings | -₩69.35b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.48k |
Gross Margin | 35.96% |
Net Profit Margin | -11.45% |
Debt/Equity Ratio | 109.0% |
How did A249420 perform over the long term?
See historical performance and comparison